A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients

Inclusion criteria: * Solid malignancy, documented by pathologic report, for which treatment with single-agent docetaxel (administered every 3 weeks, at dose \<75 mg/m2)is planned. * Written informed consent Exclusion criteria: * Patient has received more than 2 prior lines of cytotoxic-containing chemotherapy * Conditions with screening ECG repolarization difficult to interpret, or showing significant abnormalities. This includes, but is not limited to: high degree AV block, pace-maker, atrial fibrillation or flutter * QTcF \>480 msec on screening ECG The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.